# Divergent trends in the incidence and mortality of coronary events, especially in women. Evidence from Finland in 1996-2021.

Atte Kallström<sup>1</sup>, Ida Holopainen<sup>2</sup>, Oleg Kambur<sup>2</sup>, Markus Perola<sup>2,3</sup>, Veikko Salomaa<sup>2</sup>, Aki S. Havulinna<sup>2,4</sup>, Markus Ramste<sup>1</sup>\*, Juha Sinisalo<sup>1</sup>\*

#### Affiliations:

 Heart and Lung Center, Helsinki University Hospital, University of Helsinki, Helsinki, Finland
 Finnish Institute for Health and Welfare (THL), Helsinki, Finland.
 Clinical and Molecular Metabolism Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland
 Institute for Molecular Medicine Finland, FIMM-HiLIFE, Helsinki, Finland

\*Equal contribution

& Correspondence: Juha Sinisalo Heart and Lung Center, Helsinki University Hospital, University of Helsinki, Helsinki, Finland Phone: +35894711

#### 1 Abstract:

2

**Objective:** Acute coronary syndrome (ACS) incidence and case fatality (CF) have declined in the past decades, but some studies have suggested a potential stagnation in this decline. We examined how the ACS burden has evolved among persons aged 35-74 in Finland from 1996 to 2021.

Methods: We used Finnish country-wide Hospital Discharge- and Causes of Death- Registers
covering first non-fatal and fatal ACS events, totaling 69 906 442 person-years at risk. We analyzed
incidence, mortality, and 28-day CF, and their trends using negative binomial, Poisson, segmented,
and logistic regression adjusting for age and sex.

**Results:** Altogether, the analysis consisted of 186 489 non-fatal and 72 907 fatal ACS events. ACS incidence declined in men (annual percentage change (APC) -2.0% [95% CI -2.2 to -1.8]) and in older women (APC of 55-64 year old -1.5% [-1.7 to -1.2] and 65-74 year old -3.3% [-3.4 to -3.2]), but the incidence decline slowed down over the last decade. In younger women aged 35-54, incidence was unchanged during the study period. ACS mortality and CF declined (APC of the mortality in men -4.4% [-4.6 to -4.2] and in women -5.0% [-5.2 to -4.7]. APC of CF in men -2.7% [-2.8 to -2.6] and in

16 women -3.3% [-3.6 to -3.1]).

Conclusions: ACS mortality declined in all groups, but the decline in ACS incidence slowed down and even halted in women. In women aged 35-54, the incidence was unchanged during the study period. These results emphasize the need of intensified cardiovascular prevention, particularly in women.

- 21 22 23 24 25 26 27 28 29 30 Key words epidemiology, acute coronary syndrome, incidence, mortality, women 31 32 Key messages 33 34
  - <u>What is already known on this topic</u> During the last decades coronary artery disease treatment and prevention have improved worldwide which has led to a decline in ACS mortality and case fatality. However, recent studies from several countries suggest, that incidence decline has stagnated or even turned to increase, especially in younger age cohorts.
- What this study adds This study showed that incidence has ceased its decline in women aged 35-54 and has slowed down in older age groups. Together with declining mortality this results in a growing number of patients living with cardiovascular disease leading to increased healthcare costs.
- How this study might affect research, practice, or policy The alarming results of this study underline the importance of intensifying prevention, focusing especially on young and middle-aged women.
- 46

35

36

37

#### 47 Introduction

48

49 Cardiovascular disease is one of the world's leading causes of death and has been extensively researched <sup>12</sup>. Established modifiable risk factors are hypertension, dyslipidemia, diabetes mellitus, 50 and smoking. Preventive measures that target these risk factors have been shown to be effective and 51 52 have a good cost-benefit ratio<sup>3</sup>. With these measures, acute coronary syndrome (ACS) mortality rates have declined during the past decades in Western countries. Approximately one-third of total ACS 53 mortality decline is due to an increase in survival after myocardial infarction<sup>4</sup>. Compared to earlier 54 decades, patients now have fewer and less severe symptoms, and survival rates are higher. However, 55 there are worrying signs that these positive trends may not be sustainable, as shown by data from the 56 US and Australia.<sup>56</sup>. It has been proposed that the alarming increases in obesity and diabetes mellitus 57 worldwide are reflected in ACS incidence <sup>57</sup>. 58

59

In Finland, the coronary heart disease mortality rate has drastically declined during the preceding 60 decades. In the last century from 1960 to 1970 Finland's mortality rate from ACS was among the 61 highest in the world. Most of the reduction is due to improving primary and secondary prevention, 62 especially concentrating on the classical cardiovascular risk factors.<sup>8</sup> Also, a substantial part of the 63 reduction has been gained by advances in the treatment of ACS, including percutaneous coronary 64 intervention and new preventive medications <sup>9</sup>. Still, the northeastern part of Finland has a 65 substantially higher burden of CHD incidence and mortality, partly due to genetic, environmental, 66 and socioeconomic aspects <sup>8 10</sup>. Previous studies have demonstrated that the short-term case fatality 67 and 1-year prognosis of incident MI have improved in both sexes from the mid-1990s to 2002 in 68 Finland<sup>11</sup>. 69

70

71 Data on trends in ACS incidence and mortality rates, and case fatality during the last years is very sparse all over the world as well as in Finland<sup>8 12</sup>. As the Finnish electronic health care registries 72 offer reliable and comprehensive nationwide data and a long follow-up period <sup>13</sup>, we chose to analyze 73 the trends using these registries and compare our findings with available corresponding data from 74 75 other Western countries. We focused on ACS trends in the 35-74 year old population of Finland from 1996 to 2021. We hypothesized that these trends would be declining since ACS mortality in the 76 77 Western world has declined in the past and it was previously projected that age-adjusted ACS event rates would decrease in Finland until 2050<sup>14</sup>. 78 79

- 80 Methods
- 81

### 82 Study population

We collected data from Finnish country-wide registers, i.e., hospital discharges, from the Care Register for Health Care and the National Causes of Death Register with complete coverage of nonfatal and fatal ACS events, including sudden, out-of-hospital cardiac deaths. A unique personal identification number that every permanent resident in Finland receives at birth or upon immigration links the data between the registries. Altogether, the analysis consists of 186 489 non-fatal and 72 907 fatal incident ACS events.

89

We defined annual population as the population on the last day of each year, available from the
Finnish Population Information System. At the end of 2021, the population of Finland aged 35-74
was 2.8 million. The study population contributed 69 906 442 person-years at risk.

93

The information permit number for the use of the Finnish Cardiovascular Disease Register (CVDR) is THL/3624/6.02.00/2023. Permission to access the original data can be applied for through FINDATA.

#### 97 Definition of ACS events

98 The data contains only the first non-fatal and fatal ACS events, as previously classified in the WHO-99 MONICA project <sup>15</sup>. We defined the event as first (i.e., incident) for an individual if he/she had no 100 previous ACS events recorded in the HDR during the preceding 10 years. If a patient had a second 101 ACS event less than 28 days from the onset of the previous event, we considered two events as one 102 and considered only the more severe diagnosis code. We defined an ACS event fatal if the patients 103 died within 28 days from the onset of the event and CF as the proportion of fatal cases of all incident 104 cases.

105

Total ACS events include non-fatal hospitalizations for MI or unstable angina (ICD-9: 410; ICD-10: I20.0, I21-I22), and fatal events, which include deaths with CHD (ICD-9: 410-414; ICD-10: I20-I25),
cardiac arrest (ICD-10: I46), sudden death for unknown reason (Finnish ICD-9: 798, not 7980A; ICD-10: R96), or unwitnessed death (ICD-10: R98) as the underlying or direct cause of death, or deaths with MI (ICD-9: 410; ICD-10: I21-I22) as the contributing cause of death.

111

We assessed ACS incidence, mortality, and case fatality for the entire population of Finland by event age, and by event year and sex. Experimental setup is shown as flowchart in Supplemental Figure 2.

#### 115 Age groups

We calculated ACS incidence, mortality, and case fatality for the age group 35-74 and further subdivided into smaller age groups as follows 35-44, 45-54, 55-64, and 65-74. CF was an exception since the two youngest age groups were combined into one 35-54 age group to lower the random variation due to low case counts.

## 120121 Statistics

We analyzed the incidence and mortality rates, as well as the significance of their trends using Poisson or negative binomial (NB) regression models adjusting for age and sex. We used NB models instead of the Poisson model if there was evidence of overdispersion, and the NB model had a better fit for the given data. We analyzed case fatality trends using the logistic regression model.

126

We used the segmented regression model to analyze the ACS incidence, mortality, and CF trendchanges during the study period.

129

We performed age-standardization of the incidence and mortality rates using the direct method with weights from the 2011-2030 European standard population<sup>16</sup>. This standard population allows further comparison with other publications. The weights used for age-standardizing case fatality are based on the age distribution of observed coronary events in MONICA populations in the WHO-MONICA project<sup>15</sup>. However, these weights were not defined for older age groups, thus we used weights aimed at a larger age distribution and smaller age groups (Supplemental Table 2).

136

The ACS incidence and mortality rates as well as case-fatality trends are presented in the figures as
three-year moving averages, the first and the last years are counted as two-year averages.

139

We used R version 4.2.2 for all statistical analyses and considered p<0.05 as statistically significant.</li>
All tests were two-tailed. We used package "MASS" (version 7.3-58.1) for negative binomial
regression, "segmented" (version 1.6-2) for segmented regression, and "AER" (version 1.2-10) for
testing whether there was overdispersion in Poisson models. <sup>17</sup> The code used for the data analysis is
available upon reasonable request.

- 145
- 146
- 147

#### 148 **Results**

149

#### 150 Overall incidence and mortality


In men and women, ACS incidence and mortality declined overall during the study period. (Figure 1). The decline in mortality was markedly steeper than the decline in incidence. The age-standardized ACS mortality rate declined by more than two thirds (in men 65.3% and in women 71.8%) and the incidence rate declined approximately by one third in men (35.1%) and by one quarter in women (24.6%).

156

Men have approximately two times higher incidence than women in the oldest age group and four times higher incidence in younger age groups (35-54 year old) (Figure 2A&B). Men have also approximately three times higher mortality in the oldest age group (65-74 year old) and five times higher mortality rate in the other age groups (Figure 2C&D). Annual incidence and mortality changes per age group, number of cases in the age groups, mean age of each group, and p-values of trends can be seen in Table 1.







Incidence --- Mortality - Men - Women
Figure 1: Trends in incidence and mortality rates of ACS in men and women aged 35-75 years, 1996-2021. Rates include
first non-fatal I20.0, I21, and I22 cases and fatal I20-25, I46, R96 and, R98 cases. Age-standardized rates per 100 000
inhabitants were calculated with the 2013 European standard population as the reference. Observed incidence and mortality rates are presented as dots, the segmented (negative binomial) regression model's predicted values as a line and
the segmented regression model's 95%-confidence intervals for predictions as a ribbon. The rates are presented on a logarithmic scale.

- 172 173
- 174
- 175
- 176
- 177 178
- 179
- 179 180
- 10
- 181 182

Age group	Mean age	Cases (N)	Average annual change (%)	95% CI	P-value
Men	age	(14)	(70)	5578 61	I -Value
All (35-74)*	62.0	185 309	-2.01	-2.20 to -1.82	<1e-16
65-74*	69.6	84 763	-3.12	-3.29 to -2.96	<1e-16
55-64*	59.9	61 912	-2.06	-2.23 to -1.89	<1e-16
45-54*	50.4	30 985	-1.40	-1.57 to -1.22	<1e-16
35-44	40.9	7 649	-1.33	-1.63 to -1.04	<1e-16
Women					
All (35-74)*	64.7	74 087	-1.66	-1.83 to -1.48	<1e-16
65-74*	70.1	44 294	-3.28	-3.40 to -3.16	<1e-16
55-64*	60.2	20 304	-1.46	-1.70 to -1.21	<1e-16
45-54	50.5	7 818	0.20	-0.10 to 0.50	0.19
35-44	41.0	1 671	0.38	-0.25 to 1.02	0.24
		_ • / _	0.00	0.20 00 2.02	0.21
	Mortality				
Men					
All (35-74)*	64.5	56 900	-4.42	-4.59 to -4.24	<1e-16
65-74*	69.6	30 602	-4.49	-4.68 to -4.30	<1e-16
55-64*	60.4	18 028	-4.05	-4.29 to -3.82	<1e-16
45-54	50.8	6 835	-4.77	-5.09 to -4.45	<1e-16
35-44	40.7	1 435	-5.29	-5.98 to -4.60	<1e-16
Women					
All (35-74)*	66.2	16 007	-5.00	-5.21 to -4.72	<1e-16
65-74*	70.1	11 104	-5.50	-5.78 to -5.21	<1e-16
55-64	60.6	3 488	-3.84	-4.28 to -3.39	<1e-16
45-54	50.7	1 104	-4.47	-5.27 to -3.67	<1e-16
35-44	40.9	311	-4.87	-6.36 to -3.40	3.06e-10
	Case fatality				
Men					
All (35-74)	62.0	185 309	-2.71	-2.84 to -2.57	<1e-16
65-74	69.6	84 763	-2.19	-2.37 to -2.01	<1e-16
55-64	59.9	61 912	-2.75	-3.00 to -2.52	<1e-16
35-54	48.5	38 634	-4.45	-4.78 to -4.12	<1e-16
Women					
All (35-74)	64.7	74 087	-3.35	-3.58 to -3.12	<1e-16
65-74	70.1	44 294	-3.15	-3.43 to -2.88	<1e-16
55-64	60.2	20 304	-2.79	-3.28 to -2.30	<1e-16
35-54	48.9	9 489	-5.74	-6.51 to -5.00	<1e-16

Table 1: Average annual changes in acute coronary syndrome incidence, mortality, and case fatality (CF) from 1996 to
 2021. Incidence and mortality rate trends were analyzed using a Poisson or negative binomial regression model. CF
 trends were analyzed with a logistic regression model. The rate changes are presented as average annual change
 percentages during the study period. P-values represent the significance of the trend by study year.

241

242 \*Negative binomial model was used instead of Poisson model.

#### **Incidence trends** 243

The trends in ACS incidence are presented in Figure 2 A) men and B) women. In men, the incidence 244 of ACS declined significantly in all age groups during the study period (annual percentage change 245 (APC) in men -2.0% [95% CI -2.2 to -1.8]) (Table 1). Segmented regression however revealed that 246 the incidence decline has slowed down significantly overall in men and men's age groups 65-74, and 247 55-64 and halted in age group 45-54 from around 2007-2012 onwards (Supplemental Table 1, 248 Supplemental Figures 3&4A). 249

250

261

In women, the incidence rate declined significantly overall and in the older age groups (overall APC 251 -1.7 [-1.8; -1.5], among 65-74 year old -3.3% [-3.4 to -3.2]) and among 55-64 year old -1.5% [-1.7 to 252 -1.2]). The overall incidence in women did not decline after 2010 and age-specific incidence rates 253 slowed down in the older age groups from 2008-2011 (Supplemental Table 1, Supplemental Figures 254 3&4B). Importantly, in women aged 35-54, ACS incidence stayed the same for over two decades 255 (APC of 35-44 year old 0.4% [-0.3 to 1.0] and 45-54 year old 0.2% [-0.1 to 0.5]). The stagnated or 256 slowed incidence decline is mostly associated with inferior development of non-fatal incident ACS 257 258 events compared to the incidence of all ACS events (Supplemental Figure 1A-C and Supplemental Table 3). The incidence of non-fatal ACS events among young women aged 35-54 has increased 259 during the study period. 260

В А 1000 800 2000 600 400 1000 800 Incidence per 100000 600 200 400 100 80 60 200 40 100 20 80 60 10 40 2020 2016 С D 400.0 1000 800 600 200.0 400 100.0 80.0 60.0 200 40.0 Mortality per 100000 20.0 100 80 10.0 8.0 6.0 60 40 4.0 2.0 20 1.0 10 8 0.4 0.2 2008 2008 \$ 0 Year Year 65-74 -- 55-64 --- 45-54 --- 35-44 65-74 -- 55-64 --- 45-54 --- 35-44



Figure 2: Trends in incidence and mortality rates of ACS in men and women by age group, 1996-2021. A) Incidence rates of men. B) Incidence rates of women. C) Mortality rates of men. D) Mortality rates of women. Incidence rates 264 include first non-fatal I20.0, I21, and I22 and fatal I20-25, I46, R96, and R98 cases. Mortality rates include the fatal cases 265 266 as mentioned above. Age-standardized rates per 100 000 inhabitants were calculated with the 2011-2030 European standard population as the reference. Observed incidence and mortality rates are presented as dots, the segmented, Poisson 267

268 or negative binomial regression model's predicted values as a line, and the regression model's 95%-confidence intervals

- 269 for predictions as a ribbon. The rates are presented on a logarithmic scale.
- 270

#### 271 Mortality trends

272 The trends in ACS mortality are presented in Figure 2 C) men and D) women and the breakpoints in


- 273 Supplemental Figure 4C-D. The ACS mortality declined in both sexes and all age groups during the
- study period (APC of the mortality in men 4.4% [-4.6 to -4.2] and in women -5.0% [-5.2 to -4.7]).
- 275 Overall, the annual mortality change was very similar in all age groups. In women, mortality declined
- most in the oldest age group (APC -5.5% [-5.8 to -5.2]) while in men, mortality declined most in the
- 277 youngest age group (APC -5.3% [-6.0 to -4.6]). However, in younger age groups, especially in
- women, case numbers are low (Table 1).

#### 279

#### 280 28-day case-fatality trends

ACS case-fatality declined over the study period in men and women (APC of the CF in men -2.7% [-282 2.8 to -2.6] and in women -3.3% [-3.6 to -3.1]) (Figure 3A). Women exhibited lower ACS case-283 fatality rates across equivalent age groups compared to men (Figure 3B). The decline was not linear, 284 particularly in the older age groups. The case fatality stayed the same or even increased a little from 285 around 2001 to 2010, depending on age group and sex (Supplemental Table 1 and Supplemental 286 Figure 5A&B). The annual decline in case fatality was most significant in the youngest age group,

almost two times faster in women and almost as fast in men compared to the older age groups.



#### 289 Discussion

290

304

313

In this nationwide study of almost 260 000 cases, we found a declining incidence of acute coronary 291 syndrome (ACS) in the population aged 35-74 during the study period of 25 years. In young women 292 aged 35-54, however, the incidence did not decline. Also, in the oldest age groups, the declining 293 294 incidence trends were slowed down during the study period. Furthermore, the overall incidence 295 decline in women halted in the last decade. Other reports have shown that the ACS incidence trend has turned into increase, especially among younger age groups <sup>5</sup><sup>18</sup>. Our study also showed that the 296 mortality rate declined in men and women and, unlike incidence, in all age groups throughout the 297 study period. The rate of decline was approximately similar in all age groups. The decline in mortality 298 is in line with the earlier prediction <sup>14</sup>. It is also worth noting that the decline in mortality was much 299 faster than in incidence. Case fatality declined similarly to mortality in both men and women and in 300 all age groups during the study period. The decline in case fatality was most significant in the 301 youngest age group which consisted of people aged 35-54 years. The case fatality was overall much 302 lower in women than in men. 303

To understand why the incidence of ACS is no longer steadily declining, we examined the results of 305 the National FinHealth 2017 survey that has gathered information on the health of the Finnish adult 306 population and on the risk factors influencing their health <sup>19</sup>. The FinHealth study showed that the 307 proportion of smokers has declined. The study also showed that the prevalence of elevated LDL has 308 declined, but no changes in low HDL levels were seen. Alcohol abstinence has also increased. 309 310 However, dietary habits have not improved, obesity has increased, as well as the waist-to-hip ratio, and hypertension is still very common in Finland. In summary, except for obesity and diabetes, other 311 ACS-related risk factors have improved. 312

One explanation for the halted incidence decline in women aged 35-54 could be that diabetes is a 314 stronger risk factor in women than in men<sup>20</sup>, considering that diabetes prevalence has also increased 315 <sup>19 21</sup>. Also, even as smoking has lost popularity, tobacco exposure, both current and accumulated, 316 predisposes female smokers to more premature myocardial infarction than men<sup>22</sup>.\_Additionally, the 317 use of oral contraceptives, which has increased in popularity in the last decades, could have influenced 318 this negative development. However, the literature regarding their effect on the risk of ischemic heart 319 disease is unanimous <sup>23-25</sup>. In addition to these somatic factors, psychosocial factors may play a role. 320 It has been shown that women under 50 years of age who develop a myocardial infarction have more 321 psychosocial risk factors than same-aged men and depressive symptoms have been shown to be 322 associated with chronic heart disease events <sup>26</sup>. 323

324

Regarding prevention, studies have shown that primary prevention is implemented even better in women than in men, but women receive less invasive measures and guideline suggested secondary preventive medication than men after myocardial infarction. Although women have a lower risk for recurrent myocardial infarction and lower numbers of 30-day cardiovascular deaths compared to men, women are reported to have a higher rate of long-term all-cause mortality.<sup>27</sup>

330 In the older age groups, the slowing down of the incidence decline may be due to the exhaustion in 331 optimizing preventive treatment and therapeutic inertia, especially when it comes to incorporating 332 new expensive treatment modalities (e.g., PCSK9, siRNA drugs) that will be utilized in younger age 333 groups <sup>28</sup>. In addition, for all age groups, improving ACS prevention and reducing mortality beyond 334 optimal treatment of classical risk factors may require a novel avenue of targeting the residual risk<sup>29</sup> 335 that may not be related to classical risk factors but mediated through inflammation and other poorly 336 understood pathomechanisms within the vascular wall<sup>30</sup>. Recently new tools, such as polygenic risk 337 scores, have been developed to predict the residual and genetic risk of ACS<sup>31</sup>. 338

- A factor that could have an overall influence on the development of incidence and case fatality in the 21st century is the introduction of sensitive troponins to clinical practice, which have the power to detect smaller myocardial infarctions.<sup>32</sup>. Additionally, the COVID-19 pandemic may have influenced the incidence and mortality figures of the last two years as COVID-19 is a risk factor for acute coronary syndrome <sup>33</sup>.
- 345

In concordance with other recent reports <sup>34 35</sup>, we showed that ACS mortality declined steadily in 346 women and men in all age groups. Awareness of coronary artery disease might influence earlier 347 seeking of care, which results in lower mortality. Because of this favorable trend in mortality, Finland 348 is included in the moderate-risk region in Europe based on the death risk due to cardiovascular 349 disease, leaving still room for improvement as many countries in Western Europe belong to the low-350 risk region <sup>36</sup>. Taking this into account, a decline in mortality and incidence could be continuously 351 achieved and improved, especially if the treatment methods evolve and there will be more focus on 352 primary and secondary prevention. 353

354

360

Our results showed that case fatality declined rapidly in men and women, especially in the youngest age group. Finland's positive trend might be explained by the same factors as the decrease in mortality. This can also be influenced by the introduction of sensitive troponins <sup>32</sup>. In addition, we identified a plateau phase in the overall declining case fatality trend from 2002 to 2010. An explanation for this plateau phase in CF is not known.

Our study is based on comprehensive nationwide Finnish Cardiovascular Disease Register data which 361 covers all symptomatic acute coronary syndrome incidents in Finland with a long study period of 362 twenty-five years. However, the study should be interpreted with certain limitations in mind: the 363 364 underlying Finnish health care registers do not provide individual information for example ECGs or troponin levels, thus the diagnoses of the cases cannot be further verified. Additionally, silent 365 myocardial infarctions are not found in the registers. However, cardiovascular diagnoses in Finnish 366 healthcare registers have been validated and found reliable which increases the confidence in our 367 results <sup>13</sup>. 368

369

#### 370 Conclusions

371

Our study demonstrated diverging trends in different components of ACS event rates in the Finnish 372 population aged 35-74 years. The ACS mortality and CF are steeply declining, whereas the incidence 373 decline is leveling off. Notably, the decline in incidence in older age groups has slowed during the 374 last decade. Also, the overall incidence in women ceased to decline. Indirectly, this may result in an 375 increase in CAD patients in the Finnish population. Consequently, the need for treatment, secondary 376 prevention, and rehabilitation resources is likely to increase as well. Particularly alarming is the halted 377 incidence decline in women aged 35-54 years. Since the incidence of first events can be reduced by 378 primary prevention only, this emphasizes the importance of improving the primary prevention 379 measures, focusing especially on young and middle-aged women. 380

- 381
- 382 Author contributions
- 383

A.K., M.R., V.S., A.H. and J.S. wrote the manuscript. M.P., A.H., M.R, V.S., and J.S. designed the
research. A.K., M.R., V.S., A.H. and J.S. performed the research. A.K., I.H., O.K. and A.H. analyzed
the data.

- 387
- 388 Acknowledgement
- 389

390 The authors wish to acknowledge CSC – IT Center for Science, Finland, for computational resources.

391

#### **392** Funding information

M.R. received support from Sigrid Juselius Foundation, Emil Aaltonen Foundation, Biomedicum
Helsinki Foundation, Orion Research Foundation, and from Finnish Foundation for Cardiovascular
Research. V.S. was supported by the Juho Vainio Foundation. I.H. was supported by Aarne Koskelo
Foundation and Otto A. Malm Foundation.

- 398399 Conflict of Interest
- 400
- 401 V.S. has had a research collaboration with Bayer Ltd (outside the present study).
- 402 403
- 404
- 405406 References:
- 407 1. Mahmood SS, Levy D, Vasan RS, Wang TJ. The Framingham Heart Study and the epidemiology of
   408 cardiovascular disease: a historical perspective. *Lancet* 2014;383(9921):999-1008. doi:
   409 10.1016/s0140-6736(13)61752-3 [published Online First: 20130929]
- 2. Roth GA, Mensah GA, Johnson CO, et al. Global Burden of Cardiovascular Diseases and Risk Factors,
  1990–2019. *Journal of the American College of Cardiology* 2020;76(25):2982-3021. doi:
  doi:10.1016/j.jacc.2020.11.010
- 4133. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in414clinical practice. Eur Heart J 2021;42(34):3227-337. doi: 10.1093/eurheartj/ehab484
- 4. Mensah GA, Wei GS, Sorlie PD, et al. Decline in Cardiovascular Mortality: Possible Causes and Implications. *Circ Res* 2017;120(2):366-80. doi: 10.1161/circresaha.116.309115
  5. Ma L Word FM, Siegel PL, Jamal A, Tamparal Trands in Martality in the United States, 1969-2012, 44
- 417
   5. Ma J, Ward EM, Siegel RL, Jemal A. Temporal Trends in Mortality in the United States, 1969-2013. JAMA

   418
   2015;314(16):1731-39. doi: 10.1001/jama.2015.12319
- 6. O'Flaherty M, Allender S, Taylor R, et al. The decline in coronary heart disease mortality is slowing in
  young adults (Australia 1976-2006): a time trend analysis. *Int J Cardiol* 2012;158(2):193-8. doi:
  10.1016/j.ijcard.2011.01.016 [published Online First: 20110202]
- 7. Ng M, Fleming T, Robinson M, et al. Global, regional, and national prevalence of overweight and obesity
   in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease
   Study 2013. *Lancet* 2014;384(9945):766-81. doi: 10.1016/s0140-6736(14)60460-8 [published Online
   First: 20140529]
- 8. Jousilahti P, Laatikainen T, Peltonen M, et al. Primary prevention and risk factor reduction in coronary
  heart disease mortality among working aged men and women in eastern Finland over 40 years:
  population based observational study. *Bmj* 2016;352:i721. doi: 10.1136/bmj.i721 [published Online
  First: 20160301]
- 430 9. Laatikainen T, Critchley J, Vartiainen E, et al. Explaining the decline in coronary heart disease mortality in
  431 Finland between 1982 and 1997. *Am J Epidemiol* 2005;162(8):764-73. doi: 10.1093/aje/kwi274
  432 [published Online First: 20050908]
- 433 10. Havulinna AS, Pääkkönen R, Karvonen M, Salomaa V. Geographic patterns of incidence of ischemic
  434 stroke and acute myocardial infarction in Finland during 1991-2003. *Ann Epidemiol* 2008;18(3):206435 13. doi: 10.1016/j.annepidem.2007.10.008
- 11. Lehto HR, Lehto S, Havulinna AS, et al. Sex differences in short- and long-term case-fatality of myocardial
   infarction. *Eur J Epidemiol* 2011;26(11):851-61. doi: 10.1007/s10654-011-9601-6 [published Online
   First: 20110630]

- 12. Dégano IR, Salomaa V, Veronesi G, et al. Twenty-five-year trends in myocardial infarction attack and
   mortality rates, and case-fatality, in six European populations. *Heart* 2015;101(17):1413-21. doi:
   10.1136/heartjnl-2014-307310 [published Online First: 20150408]
- 13. Pajunen P, Koukkunen H, Ketonen M, et al. The validity of the Finnish Hospital Discharge Register and
  Causes of Death Register data on coronary heart disease. *Eur J Cardiovasc Prev Rehabil*2005;12(2):132-7. doi: 10.1097/00149831-200504000-00007
- 14. Salomaa V, Havulinna AS, Koukkunen H, et al. Aging of the population may not lead to an increase in the
   numbers of acute coronary events: a community surveillance study and modelled forecast of the
   future. *Heart* 2013;99(13):954-59. doi: 10.1136/heartjnl-2012-303216
- 448 15. M. Mähönen HT-P, A. Rajakangas, Z. Cepaitis, K. Kuulasmaa, A. Dobson and U. Keil. Definitions of case
   449 fatality for coronary events in the WHO MONICA Project. 2000 doi:
- 450 https://www.thl.fi/publications/monica/carpfish/appendd/cfdef.htm
- 451 16. Institute NC. Standard Population Data 2012 [cited 2023. Available from:

https://seer.cancer.gov/stdpopulations/stdpop.19ages.html.

- 453 17. R: A language and environmental for statistical computing [program]: R Foundation for Statistical
   454 Computing, 2022.
- 18. Gabet A, Danchin N, Juillière Y, Olié V. Acute coronary syndrome in women: rising hospitalizations in
  middle-aged French women, 2004-14. *Eur Heart J* 2017;38(14):1060-65. doi:
  10.1093/eurheartj/ehx097
- 458 19. P. Koponen, K. Borodulin, A. Lundqvist, et al. Terveys, toimintakyky ja hyvinvointi Suomessa, FinTerveys
   459 2017 -tutkimus, 2017.
- 460 20. Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in
   461 men and women: meta-analysis of 37 prospective cohort studies. *BMJ* 2006;332(7533):73-78. doi:
   462 10.1136/bmj.38678.389583.7C
- 463 21. M. Arffman, P. Ilanne-Parikka, I. Keskimäki, et al. Tyypin 1 ja 2 diabeteksen ja niiden lisäsairauksien
  464 ilmaantuvuus ja esiintyvys Suomessa vuosina 2000–2017. 2020 doi:
  465 <u>https://www.julkari.fi/bitstream/handle/10024/139885/URN\_ISBN\_978-952-343-501-</u>
  466 8.pdf?sequence=1&isAllowed=y
- 467 22. Grundtvig M, Hagen TP, German M, Reikvam A. Sex-based differences in premature first myocardial
   468 infarction caused by smoking: twice as many years lost by women as by men. *Eur J Cardiovasc Prev* 469 *Rehabil* 2009;16(2):174-9. doi: 10.1097/HJR.0b013e328325d7f0
- 470 23. Okoth K, Chandan JS, Marshall T, et al. Association between the reproductive health of young women
  471 and cardiovascular disease in later life: umbrella review. *Bmj* 2020;371:m3502. doi:
  472 10.1136/bmj.m3502 [published Online First: 20201007]
- 473 24. Barsky L, Shufelt C, Lauzon M, et al. Prior Oral Contraceptive Use and Longer Term Mortality Outcomes
  474 in Women with Suspected Ischemic Heart Disease. J Womens Health (Larchmt) 2021;30(3):377-84.
  475 doi: 10.1089/jwh.2020.8743 [published Online First: 20210121]
- 476 25. Bassuk SS, Manson JE. Oral contraceptives and menopausal hormone therapy: relative and attributable
  477 risks of cardiovascular disease, cancer, and other health outcomes. *Ann Epidemiol* 2015;25(3):193478 200. doi: 10.1016/j.annepidem.2014.11.004 [published Online First: 20141113]
- 479 26. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with
   480 myocardial infarction in 52 countries (the INTERHEART study): case-control study. *Lancet* 481 2004;364(9438):937-52. doi: 10.1016/s0140-6736(04)17018-9
- 27. DeFilippis EM, Collins BL, Singh A, et al. Women who experience a myocardial infarction at a young age
   have worse outcomes compared with men: the Mass General Brigham YOUNG-MI registry.
   *European Heart Journal* 2020;41(42):4127-37. doi: 10.1093/eurheartj/ehaa662
- 28. Dixon DL, Sharma G, Sandesara PB, et al. Therapeutic Inertia in Cardiovascular Disease Prevention: Time
   to Move the Bar. J Am Coll Cardiol 2019;74(13):1728-31. doi: 10.1016/j.jacc.2019.08.014
- 487 29. Toso A, Leoncini M, Maioli M, et al. Residual risk after acute coronary syndrome: the PRATO-ACS
   488 Registry. *European Heart Journal* 2021;42(Supplement\_1) doi: 10.1093/eurheartj/ehab724.2466

- 30. Del Buono MG, Montone RA, Iannaccone G, et al. Redefining residual inflammatory risk after acute
  coronary syndrome. *Future Cardiol* 2022;18(2):115-23. doi: 10.2217/fca-2021-0032 [published
  Online First: 20210816]
- 492 31. Klarin D, Natarajan P. Clinical utility of polygenic risk scores for coronary artery disease. *Nat Rev Cardiol* 493 2022;19(5):291-301. doi: 10.1038/s41569-021-00638-w [published Online First: 20211122]
- 494 32. Salomaa V, Ketonen M, Koukkunen H, et al. The effect of correcting for troponins on trends in coronary
   495 heart disease events in Finland during 1993–2002: the FINAMI study. *European Heart Journal* 496 2006;27(20):2394-99. doi: 10.1093/eurheartj/ehl120
- 497 33. Katsoularis I, Fonseca-Rodríguez O, Farrington P, et al. Risk of acute myocardial infarction and ischaemic
   498 stroke following COVID-19 in Sweden: a self-controlled case series and matched cohort study.
   499 *Lancet* 2021;398(10300):599-607. doi: 10.1016/s0140-6736(21)00896-5 [published Online First:
   500 20210729]
- 34. Neumann JT, Goßling A, Sörensen NA, et al. Temporal trends in incidence and outcome of acute
   coronary syndrome. *Clinical Research in Cardiology* 2020;109(9):1186-92. doi: 10.1007/s00392-020 01612-1
- 35. Zuin M, Rigatelli G, Temporelli P, et al. Trends in acute myocardial infarction mortality in the European
   Union, 2012–2020. European Journal of Preventive Cardiology 2023;30(16):1758-71. doi:
   10.1093/eurjpc/zwad214
- 507 36. SCORE2 wg risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in 508 Europe. *European Heart Journal* 2021;42(25):2439-54. doi: 10.1093/eurheartj/ehab309

#### 530 Supplemental Material

Supplemental Table 1: Segmented (Poisson or negative binomial) regression model's breakpoints and intervals of
 incidence, mortality, and case fatality trends. Intervals where there was no trend change are shown on a yellow
 background and increasing trends are shown on a red background.

Incidence				
Age group	Breakpoints	Interval 1 (estimate + slope [95% CI])	Interval 2 (estimate + slope [95% CI])	Interval 3 (estimate + slope [95% CI])
Men				
All (35-74)	2003, 2009	-10.398 - 0.009 [-0.020; 0.002] * year	-10.175 - 0.039 [-0.062; -0.017] * year	-10.521 - 0.013 [-0.018; -0.007] * ye
65-74	2002, 2012	-8.383 - 0.018 [-0.029; -0.007] * year	-8.215 - 0.045 [-0.053; -0.038] * year	-8.636 - 0.018 [-0.025; -0.012] * yea
55-64	2004, 2007	-8.880 - 0.018 [-0.027; -0.009] * year	-8.662 - 0.047 [-0.073; -0.020] * year	-9.045 - 0.013 [-0.017; -0.009] * yea
45-54	2003, 2009	-10.924 - 0.006 [-0.004; 0.017] * year	-10.626 - 0.037 [-0.049, -0.027] * year	-11.052 - 0.005 [-0.010; 0.000] * yea
35-44	2001	-13.973 + 0.010 [-0.015; 0.034] * year	-13.840 - 0.017 [-0.021; -0.012] * year	-
Women				
All (35-74)	2001, 2011	-12.619 + 0.012 [-0.004; 0.028] * year	-12.367 - 0.035 [-0.043; -0.026] * year	-12.810 - 0.004 [-0.011; 0.003] * yea
65-74	2001, 2011	-11.582 - 0.008 [-0.022; 0.006] * year	-11.360 - 0.051 [-0.059; -0.043] * year	-11.888 - 0.015 [-0.021; -0.011] * yea
55-64	2004, 2008	-12.083 + 0.001 [-0.010; 0.011] * year	-11.567 - 0.064 [-0.120; -0.008] * year	-12.315 - 0.001 [-0.007; 0.004] * yea
45-54	2001, 2016	-13.431 + 0.060 [0.024; 0.097] * year	-13.121 - 0.009 [-0.015; -0.002] * year	-13.881 + 0.029 [-0.007; 0.066] * yea
35-44	2000	-16.447 + 0.069 [-0.009; 0.147] * year	-16.132 - 0.003 [-0.011; 0.006] * year	-
Mortality				
Men				
All (35-74)	2020	-12.377 - 0.046 [-0.048; -0.044] * year	-13.618 + 0.007 [-0.101; 0.114] * year	-
CE 74	2005 2020	10 240 0 060 [ 0 069; 0 051] * voor	-10 504 - 0 042 [-0 046· -0 027] * voar	-12 784 ± 0.054 [-0.050: 0.016] * vor

65-74	2005, 2020	-10.349 - 0.060 [-0.068; -0.051] * year	-10.504 - 0.042 [-0.046; -0.037] * year	-12.784 + 0.054 [-0.050; 0.016] * year
55-64	2001, 2010	-11.605 - 0.055 [-0.075; -0.036] * year	-11.720 - 0.032 [-0.043; -0.021] * year	-11.477 - 0.049 [-0.058; -0.040] * year
45-54	2005, 2014	-13.462 - 0.033 [-0.046; -0.020] * year	-13.170 - 0.067 [-0.083; -0.050] * year	-13.895 - 0.027 [-0.052; -0.001] * year
35-44	-	-	-	-
Women				
All (35-74)	2006	-15.091 - 0.061 [-0.069; -0.053] * year	-15.258 - 0.044 [-0.050; -0.038] * year	-
All (35-74) 65-74	2006 2006	-15.091 - 0.061 [-0.069; -0.053] * year -14.738 - 0.079 [-0.088; -0.069] * year	-15.258 - 0.044 [-0.050; -0.038] * year -15.106 - 0.042 [-0.049; -0.035] * year	-
. ,		. , .,		-
65-74		. , .,		- - -26.779 + 0.456 [-0.136; 1.048] * year

Case fatality				
Men				
All (35-74)	2002, 2010	-2.557 - 0.060 [-0.069, -0.052] * year	-2.908 - 0.006 [-0.013, 0.002] * year	-2.473 - 0.036 [-0.041, -0.031] * year
65-74	2004, 2010	-2.059 - 0.061 [-0.070, -0.053] * year	-2.746 + 0.020 [0.002, 0.038] * year	-2.088 - 0.027 [-0.034, -0.020] * year
55-64	2001, 2010	-2.917 - 0.062 [-0.083, -0.042] * year	-3.228 - 0.000 [-0.013, 0.013] * year	-2.561 - 0.049 [-0.057, -0.041] * year
35-54	-	-	-	-
Women				
All (35-74)	2004, 2009	-2.881 - 0.075 [-0.088, -0.063] * year	-3.491 + 0.004 [-0.017, 0.026] * year	-2.959 - 0.036 [-0.045, -0.028] * year
65-74	2004, 2010	-3.380 - 0.085 [-0.099, -0.070] * year	-4.142 + 0.012 [-0.016, 0.04] * year	-3.582 - 0.029 [-0.040, -0.019] * year
55-64	2012	-3.724 - 0.021 [-0.030, -0.012] * year	-3.244 - 0.050 [-0.077, -0.023] * year	-
35-54	-	-	-	-

Age (years)	Weights
0-4	1
5-9	1
10-14	1
15-19	1
20-24	1
25-29	1
30-34	2
35-39	5
40-44	9
45-49	16
50-54	26
55-59	42
60-64	56
65-69	75
70-74	93
75-79	100
80-84	100
85-	100


Supplemental Table 2: The weights for age-standardizing case fatality. Based on the age distribution of observed
 coronary events in MNICA populations in the WHO-MONICA project.

536

Supplemental Table 3: Average annual changes in acute coronary syndrome non-fatal incident incidence from 1996 to
 2021. Incidence rate trends were analyzed using a Poisson or negative binomial regression model. The rate changes are
 presented as average annual change percentages during the study period. P-values represent the significance of the trend
 by study year.


Incidence				
Age group	Average annual change (%)	95% CI	P-value	
Men				
All (35-74)*	-1.16	-1.37 to -0.95	5.70e-27	
65-74*	-2.35	-2.55 to -2.16	3.56e-123	
55-64*	-1.25	-1.44 to -1.06	1.09e-35	
45-54*	-0.47	-0.67 to -0.26	6.26e-6	
35-44	-0.44	-0.77 to -0.12	0.008	
Women				
All (35-74)*	-0.92	-1.11 to -0.71	1.16e-18	
65-74*	-2.48	-2.69 to -2.27	6.27e-117	
55-64*	-0.97	-1.24 to -0.71	1.36e-12	
45-54	0.96	0.64 to 1.29	5.65e-9	
35-44	1.57	0.86 to 2.29	1.35e-5	

541 \*Negative binomial model was used instead of Poisson model.



Supplemental Figure 1: Trends in incidence of first non-fatal ACS incidents in men and women by age group, 1996-2021. A. Incidence rates of men and women aged 35-74. B. Incidence rates of men in 10-year age groups. C. Incidence rates of women in 10-year age groups. Incidence rates include first non-fatal I20.0, I21, and I22 cases. Agestandardized incidence rates per 100 000 inhabitants were calculated with the 2011-2030 European standard population as the reference. Observed incidences are presented as dots, the segmented (Poisson or negative binomial) regression model predicted values as a line and the segmented regression model 95%confidence intervals for predictions as a ribbon. The rates are presented on a logarithmic scale.


- 542
- 543
- 544
- 545
- 546
- 547
- 548
- 549




Incidence and mortality rates, and the significance of their trends analyzed with
 Poisson and negative binomial regression models. Case fatality analyzed with logistics
 regression model. Trend changes further analyzed with segmented regression model.

551 Supplemental Figure 2: Flowchart of the study population and methods.


- 552
- 553



555 Supplemental Figure 3: Trends in incidence and mortality rates of acute coronary syndrome in men and women aged 556 35-75 years, 1996-2021. Rates include first non-fatal I20.0, I21, and I22 cases and fatal I20-25, I46, R96 and, R98 557 cases. Age-standardized rates per 100 000 inhabitants were calculated with the 2013 European standard population as 558 the reference. Observed incidence and mortality rates are presented as dots, the segmented (negative binomial) 559 regression model's predicted values as a line, and the regression model's 95%-confidence intervals for predictions as a 550 ribbon. Breakpoints where there is significant trend change are marked as vertical dashed lines. The rates are presented 551 on a logarithmic scale.



Supplemental Figure 4: Trends in incidence and mortality rates of acute coronary syndrome in men and women by age group, 1996-2021. A) Incidence rates of men, and B) women. C) Mortality rates of men, and D) women. Incidence rates include first non-fatal I20.0, I21, and I22 and fatal I20-25, I46, R96, and R98 cases. Mortality rates include the fatal cases as mentioned above. Age-standardized rates per 100 000 inhabitants were calculated with the 2011-2030 European standard population as the reference. Observed incidence and mortality rates are presented as dots, the segmented, Poisson or negative regression model's predicted values as a line, and the regression model's 95%-confidence intervals for predictions as a ribbon. Breakpoints where there is significant trend change are marked as vertical dashed lines. The rates are presented on a logarithmic scale. 



Supplemental Figure 5: Trends in case fatality (CF) of acute coronary syndrome A) among men and women aged 3574, and B) by 10-year age groups, 1996-2021. CF includes the first non-fatal I20.0, I21, and I22 and fatal I20-25, I46,
R96, and R98 cases. CF was age-standardized using weights based on the age distribution of observed coronary events
in populations participating in the WHO-MONICA project. Observed case-fatality is presented as dots, the segmented
or logistic regression model's predicted values as a line, and the regression model's 95%-confidence intervals for
predictions as a ribbon. Breakpoints where there is significant trend change are marked as vertical dashed lines.